Organoid Biobank

The Organoid Biobank created by HUB and its partners consists of more than 800 organoid cultures representing a variety of organs and disease models. For monogenetic diseases, the HUB Organoid biobank includes intestinal and lung organoids from cystic fibrosis patients and liver organoids from patients with metabolic diseases (alpha-1 antitrypsin, Crigler-Najjar, etc.). The HUB Organoid biobank also has an important representation of cancer models including colorectal, intestinal pancreatic, lung and breast tumour organoids. For some of these cancer models, organoids derived from normal (cancer-free) adjacent tissue are also available.

Using the Living Biobank, HUB explores novel therapeutic strategies, including responsiveness to drug combinations to develop rules for patient stratification based on drug sensitivity in vitro. Connecting genomic heterogeneity and gene function to in vitro drug responsiveness will lead to the development of a road map for improved treatment strategies.

HUB Organoid Database

HUB Organoid database is a HUB and the Cancer Genomics Centre initiative. It consists of a catalogue of all models that are present in the HUB Organoid biobank. Extensive information about practical aspects of the organoid cultures and their characterisation, including genetic, transcriptional, histological and clinical data, can be found in the organoid database, depending on the model. If available, responses to relevant drug treatments for the disease model are also provided.

go to database
Contact us